214 related articles for article (PubMed ID: 26664853)
21. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
22. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.
Woo JT; Kawatani M; Kato M; Shinki T; Yonezawa T; Kanoh N; Nakagawa H; Takami M; Lee KH; Stern PH; Nagai K; Osada H
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4729-34. PubMed ID: 16537392
[TBL] [Abstract][Full Text] [Related]
23. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
24. Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone.
Roux S; Quinn J; Pichaud F; Orcel P; Chastre E; Jullienne A; De Vernejoul MC
J Cell Physiol; 1996 Sep; 168(3):489-98. PubMed ID: 8816903
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
Morko J; Kiviranta R; Mulari MT; Ivaska KK; Väänänen HK; Vuorio E; Laitala-Leinonen T
Bone; 2009 Apr; 44(4):717-28. PubMed ID: 19118660
[TBL] [Abstract][Full Text] [Related]
26. Bone resorption by isolated osteoclasts in living versus devitalized bone: differences in mode and extent and the effects of human recombinant tissue inhibitor of metalloproteinases.
Shimizu H; Sakamoto M; Sakamoto S
J Bone Miner Res; 1990 Apr; 5(4):411-8. PubMed ID: 2343781
[TBL] [Abstract][Full Text] [Related]
27. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals.
Møller AMJ; Delaisse JM; Olesen JB; Bechmann T; Madsen JS; Søe K
JBMR Plus; 2020 Nov; 4(11):e10412. PubMed ID: 33210064
[TBL] [Abstract][Full Text] [Related]
29. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.
Selander K; Lehenkari P; Väänänen HK
Calcif Tissue Int; 1994 Nov; 55(5):368-75. PubMed ID: 7532540
[TBL] [Abstract][Full Text] [Related]
30. Comparison of osteoclastogenesis and resorption activity of human osteoclasts on tissue culture polystyrene and on natural extracellular bone matrix in 2D and 3D.
Kleinhans C; Schmid FF; Schmid FV; Kluger PJ
J Biotechnol; 2015 Jul; 205():101-10. PubMed ID: 25562421
[TBL] [Abstract][Full Text] [Related]
31. [V-ATPase inhibitor baflomycine A1 inhibits bone resorption by osteoclast-like cells].
Zhao N; Yu S
Zhonghua Bing Li Xue Za Zhi; 1999 Dec; 28(6):436-9. PubMed ID: 11869558
[TBL] [Abstract][Full Text] [Related]
32. Measurement by vertical scanning profilometry of resorption volume and lacunae depth caused by osteoclasts on dentine slices.
Pascaretti-Grizon F; Mabilleau G; Basle MF; Chappard D
J Microsc; 2011 Feb; 241(2):147-52. PubMed ID: 21118208
[TBL] [Abstract][Full Text] [Related]
33. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
34. CD34 human hematopoietic progenitor cell line, MUTZ-3, differentiates into functional osteoclasts.
Ciraci E; Barisani D; Parafioriti A; Formisano G; Arancia G; Bottazzo G; Berardi AC
Exp Hematol; 2007 Jun; 35(6):967-77. PubMed ID: 17533051
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.
Roato I; Grano M; Brunetti G; Colucci S; Mussa A; Bertetto O; Ferracini R
FASEB J; 2005 Feb; 19(2):228-30. PubMed ID: 15550550
[TBL] [Abstract][Full Text] [Related]
36. IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts.
Trebec-Reynolds DP; Voronov I; Heersche JN; Manolson MF
J Cell Biochem; 2010 Apr; 109(5):975-82. PubMed ID: 20108252
[TBL] [Abstract][Full Text] [Related]
37. [Possible mechanism of the specific action of bisphosphonates on osteoclasts].
Udagawa N
Nihon Rinsho; 2003 Feb; 61(2):207-12. PubMed ID: 12638209
[TBL] [Abstract][Full Text] [Related]
38. In vitro osteoclast resorption of bone substitute biomaterials used for implant site augmentation: a pilot study.
Taylor JC; Cuff SE; Leger JP; Morra A; Anderson GI
Int J Oral Maxillofac Implants; 2002; 17(3):321-30. PubMed ID: 12074446
[TBL] [Abstract][Full Text] [Related]
39. Measurement of osteoclastic resorption pits with a tandem scanning microscope.
Boyde A; Dillon CE; Jones SJ
J Microsc; 1990 May; 158(Pt 2):261-5. PubMed ID: 2370654
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of osteoclast activity and bone turnover in different skeletal sites.
Goldberg S; Grynpas MD; Glogauer M
Arch Oral Biol; 2016 Nov; 71():134-143. PubMed ID: 27505033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
